BioMarin Pharmaceutical ( BMRN -4.44%), a leader in treatments for rare genetic disorders, released its Q3 2024 earnings on ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President - Finance; Biomarin Pharmaceutical Inc ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

Gena Wang, an analyst from Barclays, maintained the Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The associated price ...

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President - Finance; Biomarin Pharmaceutical Inc ...